Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156559 · ClinicalTrials.gov registry record
MMR and Varicella Vaccine in Premature Infants
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 32
- Enrollment target
NCT00156559 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 32 participants.
The verdict
NCT00156559 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
This research is designed to address the question, "Does the relative deficit in vaccine immunogenicity in extremely premature infants persist beyond the first 6 months of life?" We propose to measure the immunogenicity of varicella and mumps-measles-rubella vaccines in relatively healthy, 12-to-15 month-old children born at \<29 weeks gestation, when compared to full-term infants, as measured by the relevant viral serologies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00156559
The ClinicalTrials.gov registry entry for NCT00156559 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00156559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00156559 about?
NCT00156559 is a clinical study titled "MMR and Varicella Vaccine in Premature Infants". This research is designed to address the question, "Does the relative deficit in vaccine immunogenicity in extremely premature infants persist beyond the first 6 months of life?" We propose to measure the immunogenicity of varicella and mumps-measles-rubella vaccines in relatively healthy, 12-to-15 ...
What is the current status of trial NCT00156559?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2004-01. Estimated completion is 2005-05.
Who is sponsoring clinical trial NCT00156559?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.